Literature DB >> 19837943

E2F1 induces pituitary tumor transforming gene (PTTG1) expression in human pituitary tumors.

Cuiqi Zhou1, Kolja Wawrowsky, Serguei Bannykh, Shiri Gutman, Shlomo Melmed.   

Abstract

Rb/E2F is dysregulated in murine and human pituitary tumors. Pituitary tumor transforming gene (PTTG1), a securin protein, is required for pituitary tumorigenesis, and PTTG1 deletion attenuates pituitary tumor development in Rb(+/-) mice. E2F1 and PTTG1 were concordantly overexpressed in 29 of 46 Rb(+/-) murine pituitary tissues and also in 45 of 80 human pituitary tumors (P < 0.05). E2F1 specifically bound the hPTTG1 promoter as assessed by chromatin immunoprecipitation and biotin-streptavidin pull-down assay, indicating that hPTTG1 may act as a direct E2F1 target. Transfection of E2F1 and its partner DP1 dose-dependently activated hPTTG1 transcription up to 3-fold in p53-devoid H1299 cells but not in p53-replete HCT116 cells. E2F1 overexpression enhanced endogenous hPTTG1 mRNA and protein levels up to 3-fold in H1299 cells. The presence of endogenous p53/p21 constrained the induction, whereas knocking down either p53 or p21 in HCT116 cells restored E2F1-induced hPTTG1 transactivation and expression. Moreover, suppressing Rb by small interfering RNA concordantly elevated E2F1 and hPTTG1 protein levels. In contrast, transfection of E2F1 small interfering RNA lowered hPTTG1 levels 24 h later in HCT116 than in H1299 cells, indicating that p53 delays E2F1 action on hPTTG1. These results elucidate a mechanism for abundant tumor hPTTG1 expression, whereby Rb inactivation releases E2F1 to induce hPTTG1. This signaling pathway may underlie the requirement of PTTG1 for pituitary tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19837943      PMCID: PMC2796149          DOI: 10.1210/me.2009-0161

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  54 in total

1.  Expression of pituitary-tumour transforming gene in colorectal tumours.

Authors:  A P Heaney; R Singson; C J McCabe; V Nelson; M Nakashima; S Melmed
Journal:  Lancet       Date:  2000-02-26       Impact factor: 79.321

2.  Pituitary tumor transforming gene overexpression facilitates pituitary tumor development.

Authors:  Ines Donangelo; Shiri Gutman; Eva Horvath; Kalman Kovacs; Kolja Wawrowsky; Michael Mount; Shlomo Melmed
Journal:  Endocrinology       Date:  2006-06-29       Impact factor: 4.736

3.  Human securin, hPTTG, is associated with Ku heterodimer, the regulatory subunit of the DNA-dependent protein kinase.

Authors:  F Romero; M C Multon; F Ramos-Morales; A Domínguez ; J A Bernal; J A Pintor-Toro; M Tortolero
Journal:  Nucleic Acids Res       Date:  2001-03-15       Impact factor: 16.971

Review 4.  Signaling processes in tumoral neuroendocrine pituitary cells as potential targets for therapeutic drugs.

Authors:  Marcelo Paez-Pereda; Damiana Giacomini; Carlos Echenique; Günter K Stalla; Florian Holsboer; Eduardo Arzt
Journal:  Curr Drug Targets Immune Endocr Metabol Disord       Date:  2005-09

5.  Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study.

Authors:  Mariagiovanna Filippella; Françoise Galland; Michèle Kujas; Jacques Young; Antongiulio Faggiano; Gaetano Lombardi; Annamaria Colao; Geri Meduri; Philippe Chanson
Journal:  Clin Endocrinol (Oxf)       Date:  2006-10       Impact factor: 3.478

6.  HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity.

Authors:  Monica Fedele; Rosa Visone; Ivana De Martino; Giancarlo Troncone; Dario Palmieri; Sabrina Battista; Andrea Ciarmiello; Pierlorenzo Pallante; Claudio Arra; Rosa Marina Melillo; Kristian Helin; Carlo Maria Croce; Alfredo Fusco
Journal:  Cancer Cell       Date:  2006-06       Impact factor: 31.743

7.  Mechanisms for growth factor-induced pituitary tumor transforming gene-1 expression in pituitary folliculostellate TtT/GF cells.

Authors:  G Vlotides; M Cruz-Soto; T Rubinek; T Eigler; C J Auernhammer; S Melmed
Journal:  Mol Endocrinol       Date:  2006-09-07

8.  Pituitary tumor transforming gene causes aneuploidy and p53-dependent and p53-independent apoptosis.

Authors:  R Yu; A P Heaney; W Lu; J Chen; S Melmed
Journal:  J Biol Chem       Date:  2000-11-24       Impact factor: 5.157

Review 9.  Genetics and proteomics of pituitary tumors.

Authors:  Sylvia L Asa; Shereen Ezzat
Journal:  Endocrine       Date:  2005-10       Impact factor: 3.633

10.  E2f1, E2f2, and E2f3 control E2F target expression and cellular proliferation via a p53-dependent negative feedback loop.

Authors:  Cynthia Timmers; Nidhi Sharma; Rene Opavsky; Baidehi Maiti; Lizhao Wu; Juan Wu; Daniel Orringer; Prashant Trikha; Harold I Saavedra; Gustavo Leone
Journal:  Mol Cell Biol       Date:  2007-01       Impact factor: 4.272

View more
  17 in total

1.  Deregulation of Rb-E2F1 axis causes chromosomal instability by engaging the transactivation function of Cdc20-anaphase-promoting complex/cyclosome.

Authors:  Somsubhra Nath; Abhishek Chowdhury; Sanjib Dey; Anirban Roychoudhury; Abira Ganguly; Dibyendu Bhattacharyya; Susanta Roychoudhury
Journal:  Mol Cell Biol       Date:  2014-11-03       Impact factor: 4.272

Review 2.  Pathogenesis of pituitary tumors.

Authors:  Shlomo Melmed
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

3.  Gene Expression in Mouse Thyrotrope Adenoma: Transcription Elongation Factor Stimulates Proliferation.

Authors:  Peter Gergics; Helen C Christian; Monica S Choo; Adnan Ajmal; Sally A Camper
Journal:  Endocrinology       Date:  2016-07-19       Impact factor: 4.736

4.  Long noncoding RNA CCAT2 is activated by E2F1 and exerts oncogenic properties by interacting with PTTG1 in pituitary adenomas.

Authors:  Dongxia Fu; Yunna Zhang; Haibin Cui
Journal:  Am J Cancer Res       Date:  2018-02-01       Impact factor: 6.166

5.  Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease.

Authors:  Ning-Ai Liu; Takako Araki; Daniel Cuevas-Ramos; Jiang Hong; Anat Ben-Shlomo; Yukiko Tone; Masahide Tone; Shlomo Melmed
Journal:  J Clin Endocrinol Metab       Date:  2015-05-05       Impact factor: 5.958

6.  ECT2/PSMD14/PTTG1 axis promotes the proliferation of glioma through stabilizing E2F1.

Authors:  Tongle Zhi; Kuan Jiang; Xiupeng Xu; Tianfu Yu; Fengqi Zhou; Yingyi Wang; Ning Liu; Junxia Zhang
Journal:  Neuro Oncol       Date:  2019-03-18       Impact factor: 12.300

7.  A Novel Expression Profile of Cell Cycle and DNA Repair Proteins in Nonfunctioning Pituitary Adenomas.

Authors:  Derya Metin-Armagan; Nil Comunoglu; Gulay Bulut; Pinar Kadioglu; Hiraku Kameda; Nurperi Gazioglu; Necmettin Tanriover; Melek Ozturk
Journal:  Endocr Pathol       Date:  2020-03       Impact factor: 3.943

8.  Analysis of regulatory networks constructed based on gene coexpression in pituitary adenoma.

Authors:  Jie Gong; Bo Diao; Guo Jie Yao; Ying Liu; Guo Zheng Xu
Journal:  J Genet       Date:  2013-12       Impact factor: 1.166

Review 9.  The role of genetic and epigenetic changes in pituitary tumorigenesis.

Authors:  Hidenori Fukuoka; Yutaka Takahashi
Journal:  Neurol Med Chir (Tokyo)       Date:  2014-11-29       Impact factor: 1.742

10.  Transgenesis-mediated reproductive dysfunction and tumorigenesis: effects of immunological neutralization.

Authors:  Ruchi Sachdeva; Neetu Bhardwaj; Ilpo Huhtaniemi; Usha Aggrawal; Swatantra Kumar Jain; Rana Zaidi; Om Singh; Rahul Pal
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.